“NCI National Clinical Trials Network - Network Lead Academic Participating Sites”

–NCI 国家临床试验网络 - 网络主导学术参与站点 –

• 批准号: 10734623
• 负责人: Konstantin H. Dragnev
• 金额: $ 19.99万
• 依托单位: DARTMOUTH-HITCHCOCK CLINIC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-11-04 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10734623
• 关键词: Address; Advanced Malignant Neoplasm; American College of Radiology Imaging Network; Back; Basic Science; Cancer Patient; Cancer and Leukemia Group B; Caring; Catchment Area; Clinical Cancer Center; Clinical Oncology; Clinical Research; Clinical Trials; Clinical Trials Cooperative Group; Comprehensive Cancer Center; Consent; Development; Disease; Eastern Cooperative Oncology Group; Eligibility Determination; Enrollment; Geographic Locations; Geography; Health; Image; Immunologics; Industry; Institution; Intervention; Lead; Leadership; Malignant Neoplasms; Mission; Molecular; Multi-Institutional Clinical Trial; NCI Center for Cancer Research; National Cancer Institute; National Clinical Trials Network; New England; New Hampshire; Norris Cotton Cancer Center; Nursing Research; Oncology; Oncology Group; Patient Selection; Patients; Performance; Phase; Process; Recording of previous events; Reporting; Research Personnel; Science; Services; Site; System; Target Populations; Translating; Vermont; cancer imaging; cancer therapy; clinical application; college; community based practice; design; innovation; medical schools; medical specialties; member; multimodality; operation; patient population; programs; rare cancer; screening; symposium; treatment trial

Abstract Norris Cotton Cancer Center (NCCC), the keystone of the cancer-related activities of both Dartmouth College, including its Geisel School of Medicine, and Dartmouth-Hitchcock Health, will participate in the NCI's National Clinical Trials Network as a Lead Academic Participating Site. NCCC has a long history of leadership in national cooperative group clinical trials, dating back to serving as an operating center for CALGB, and more recently as a main member of the Alliance for Clinical Trial in Oncology, NRG, COG, and ECOG/ACRIN. As the only NCI designated Comprehensive Cancer Center in northern New England, NCCC currently serves annually over 5,000 new patients and 30,000 returning cancer patients. NCCC is the specialty academic center for Vermont and New Hampshire, anchoring a network of 17 community-based practice sites across the region and receiving referrals of rare and advanced cancers, the target population for enrollment on innovative clinical trials, from a large geographic catchment area. Within Dartmouth, NCCC has a central Office of Clinical Research (OCR) which coordinates full participation in the entire range of available clinical trials. NCCC intends to participate fully in all NCTN activities, expanding its prior focus on participation in the Alliance. NCCC investigators are active in many NCTN Operations Center committees, facilitating a bi-directional integration of NCCC concepts into the NCTN, while NCTN studies will be seamless incorporated into the NCCC trial portfolio. We anticipate accrual of 55 consented subjects on high performance intervention for treatment trials and 20 subjects on screening only accruals for treatment or imaging trials. Care at DH is organized into 17 designated interdisciplinary disease-based teams which bring together all relevant specialties, 14 on a weekly basis, for new patient conferences at which eligibility for enrollment on clinical trials is assessed routinely. NCCC research nurses assigned to these Clinical Oncology Groups (COGs) are responsible for keeping the teams informed of available trials, and the NCCC clinical trials management system (Velos eResearch) provides the teams reports tracking current enrollment. While highest priority is given to translating NCCC science into clinical application, Dartmouth's size precludes most single-institution studies, and national cooperative group trials are prioritized ahead of industry-initiated studies for fulfillment of NCCC's clinical research mission.

摘要 诺里斯棉花癌症中心（NCCC），达特茅斯学院， 包括其盖泽尔医学院和达特茅斯-希区柯克健康中心，将参加NCI的国家 临床试验网络作为主要学术参与网站。NCCC有着悠久的领导历史， 国家合作组临床试验，可以追溯到作为一个操作中心的CALGB，等等 最近作为肿瘤临床试验联盟、NRG、COG和ECOG/ACRIN的主要成员。作为 作为北方新英格兰唯一一家NCI指定的综合癌症中心，NCCC目前为 每年有超过5,000名新病人和30,000名返回的癌症病人。NCCC是专业学术中心 为佛蒙特州和新罕布什尔州，在该地区建立了一个由17个社区实践点组成的网络 并接受罕见和晚期癌症的转诊， 试验，从一个大的地理集水区。在达特茅斯内，NCCC设有一个中心临床办公室， 研究（OCR），协调全面参与整个范围的可用临床试验。NCCC 打算全面参与NCTN的所有活动，扩大其先前对参与联盟的关注。 NCCC调查人员在许多NCTN运营中心委员会中非常活跃， 将NCCC概念整合到NCTN中，而NCTN的研究将无缝地整合到 NCCC试验组合。我们预计将有55名知情同意的受试者接受高性能干预， 治疗试验和20名受试者在筛选仅累积治疗或成像试验。卫生署的护理 组织成17个指定的跨学科疾病小组，汇集所有相关的 专科，每周14次，用于新患者会议，在会议上有资格参加临床试验 定期评估。分配到这些临床肿瘤组（COG）的NCCC研究护士是 负责向团队通报可用的试验和NCCC临床试验管理 系统（Velos eResearch）提供了跟踪当前入组的团队报告。最高优先级是 由于致力于将NCCC科学转化为临床应用，达特茅斯的规模排除了大多数单一机构 研究和国家合作组试验优先于行业发起的研究，以实现 NCCC的临床研究使命。